Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACIU AC Immune	$1.95 -5.8%	$1.68	$1.43 ▼ $4.41	$195.80M	1.57	152,378 shs	134,136 shs
AVBP ArriVent BioPharma	$23.27 -1.5%	$20.41	$15.47 ▼ $36.37	$796.14M	1.26	202,498 shs	441,320 shs
IMNM Immunome	$9.20 -6.0%	$8.22	$5.15 ▼ $16.81	$851.85M	1.94	921,691 shs	1.26 million shs
PHAR Pharming Group	$10.87 -6.0%	$9.63	$6.65 ▼ $12.61	$731.33M	0.02	6,238 shs	3,787 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACIU AC Immune	0.00%	-4.41%	+24.20%	-14.85%	-57.97%
AVBP ArriVent BioPharma	0.00%	-1.06%	+20.95%	+10.81%	+24.71%
IMNM Immunome	0.00%	+0.77%	+15.00%	+4.90%	-42.50%
PHAR Pharming Group	0.00%	-8.96%	+19.07%	+23.96%	+31.77%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACIU AC Immune	2.9774 of 5 stars	3.5	3.0	3.3	0.8	1.3
AVBP ArriVent BioPharma	1.4643 of 5 stars	3.6	0.0	3.1	0.8	0.0
IMNM Immunome	1.6186 of 5 stars	3.5	0.0	2.3	2.5	0.0
PHAR Pharming Group	2.1728 of 5 stars	3.5	3.0	2.6	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACIU AC Immune	3.00	Buy	$12.00	515.38% Upside
AVBP ArriVent BioPharma	3.14	Buy	$39.29	68.83% Upside
IMNM Immunome	3.00	Buy	$23.33	153.62% Upside
PHAR Pharming Group	3.00	Buy	$30.00	175.96% Upside

Current Analyst Ratings Breakdown

Latest ACIU, AVBP, IMNM, and PHAR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/20/2025	AVBP ArriVent BioPharma	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$40.00
5/14/2025	AVBP ArriVent BioPharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$39.00 ➝ $40.00
5/13/2025	IMNM Immunome	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$33.00 ➝ $21.00
5/1/2025	ACIU AC Immune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $12.00
4/3/2025	ACIU AC Immune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/2/2025	IMNM Immunome	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$23.00
3/20/2025	AVBP ArriVent BioPharma	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$37.00
3/20/2025	IMNM Immunome	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$33.00 ➝ $33.00
3/20/2025	IMNM Immunome	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$30.00 ➝ $30.00
3/20/2025	IMNM Immunome	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$35.00 ➝ $25.00
3/20/2025	PHAR Pharming Group	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$37.00 ➝ $37.00

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACIU AC Immune	$28.30M	6.92	N/A	N/A	$2.12 per share	0.92
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	($4.79) per share	N/A
IMNM Immunome	$10.94M	73.19	N/A	N/A	$2.77 per share	3.32
PHAR Pharming Group	$320.71M	2.31	$0.12 per share	91.82	$3.26 per share	3.33

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACIU AC Immune	-$60.41M	-$0.58	N/A	N/A	N/A	N/A	-28.26%	-18.98%	8/5/2025 (Estimated)
AVBP ArriVent BioPharma	-$69.33M	-$3.77	N/A	N/A	N/A	N/A	-43.89%	-29.67%	8/13/2025 (Estimated)
IMNM Immunome	-$106.81M	-$3.18	N/A	N/A	N/A	-3,014.59%	-48.63%	-41.62%	8/11/2025 (Estimated)
PHAR Pharming Group	-$10.55M	-$0.20	N/A	362.37	N/A	-6.09%	-7.65%	-3.82%	7/30/2025 (Estimated)

Latest ACIU, AVBP, IMNM, and PHAR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	AVBP ArriVent BioPharma	-$0.66	-$1.90	-$1.24	-$1.90	N/A	N/A
5/12/2025	Q1 2025	IMNM Immunome	-$0.66	-$0.52	+$0.14	-$0.52	$0.46 million	$2.93 million
5/8/2025	Q1 2025	PHAR Pharming Group	-$0.25	-$0.22	+$0.03	-$0.22	$67.74 million	$79.09 million
4/30/2025	Q1 2025	ACIU AC Immune	-$0.22	-$0.21	+$0.01	-$0.21	$1.99 million	$1.12 million
3/19/2025	Q4 2024	IMNM Immunome	-$0.68	-$0.84	-$0.16	-$1.28	$3.07 million	$2.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACIU AC Immune	N/A	N/A	N/A	N/A	N/A
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	N/A
IMNM Immunome	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACIU AC Immune	N/A	1.86	1.86
AVBP ArriVent BioPharma	N/A	19.28	19.28
IMNM Immunome	N/A	6.17	6.17
PHAR Pharming Group	0.41	3.53	2.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACIU AC Immune	51.36%
AVBP ArriVent BioPharma	9.48%
IMNM Immunome	44.58%
PHAR Pharming Group	0.03%

Insider Ownership

Company	Insider Ownership
ACIU AC Immune	4.60%
AVBP ArriVent BioPharma	18.58%
IMNM Immunome	8.60%
PHAR Pharming Group	2.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACIU AC Immune	140	100.41 million	94.39 million	Optionable
AVBP ArriVent BioPharma	40	34.21 million	N/A	N/A
IMNM Immunome	40	87.01 million	72.92 million	Optionable
PHAR Pharming Group	280	68.03 million	66.62 million	Not Optionable

ACIU, AVBP, IMNM, and PHAR Headlines

Recent News About These Companies

Short Interest in Pharming Group (NASDAQ:PHAR) Expands By 169.2%

June 13 at 7:24 PM | marketbeat.com

European Penny Stocks Under €200M Market Cap To Watch

June 13 at 10:55 AM | uk.finance.yahoo.com

Pharming Group (NASDAQ:PHAR) Trading 3.9% Higher - Here's What Happened

June 12 at 1:20 PM | marketbeat.com

Pharming Group reports on results of the 2025 Annual General Meeting of Shareholders

June 11, 2025 | finance.yahoo.com

Pharming Group Announces Key Board Appointments and Approvals at 2025 AGM

June 11, 2025 | tipranks.com

Pharming Group (NASDAQ:PHAR) Sees Large Volume Increase - Here's Why

June 11, 2025 | marketbeat.com

Pharming Group (NASDAQ:PHAR) Shares Down 4.6% - Here's What Happened

June 10, 2025 | marketbeat.com

Pharming Group (NASDAQ:PHAR) Trading Up 6.7% - Here's Why

June 8, 2025 | americanbankingnews.com

Pharming Group (NASDAQ:PHAR) Stock Price Up 6.7% - Here's What Happened

June 6, 2025 | marketbeat.com

Pharming Group (NASDAQ:PHAR) Shares Gap Down - Should You Sell?

June 5, 2025 | marketbeat.com

Pharming Group (NASDAQ:PHAR) Shares Gap Up - Here's What Happened

June 4, 2025 | marketbeat.com

Pharming Group (NASDAQ:PHAR) Reaches New 1-Year High - What's Next?

June 3, 2025 | marketbeat.com

Pharming Group (NASDAQ:PHAR) Sees Large Decline in Short Interest

June 3, 2025 | marketbeat.com

Pharming Group (NASDAQ:PHAR) Stock Price Up 10.1% - Here's What Happened

May 31, 2025 | marketbeat.com

Pharming Group to participate in June investor conferences

May 28, 2025 | finance.yahoo.com

Pharming Group to participate in June investor conferences | PHARM Stock News

May 28, 2025 | gurufocus.com

Pharming Group First Quarter 2025 Earnings: US$0.022 loss per share (vs US$0.019 loss in 1Q 2024)

May 10, 2025 | finance.yahoo.com

Pharming Group N.V. (PHAR) Q1 2025 Earnings Call Transcript

May 9, 2025 | seekingalpha.com

Pharming Group N.V. 2025 Q1 - Results - Earnings Call Presentation

May 9, 2025 | seekingalpha.com

Pharming Group’s Strong Financial Performance and Strategic Growth Drive Buy Rating

May 8, 2025 | tipranks.com

Pharming Group N.V.: Pharming Group reports first quarter 2025 financial results and provides business update

May 8, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACIU, AVBP, IMNM, and PHAR Company Descriptions

AC Immune NASDAQ:ACIU

$1.95 -0.12 (-5.80%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.97 +0.02 (+1.03%)

As of 06/13/2025 07:50 PM Eastern

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

ArriVent BioPharma NASDAQ:AVBP

$23.27 -0.36 (-1.52%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$23.26 -0.02 (-0.06%)

As of 06/13/2025 04:02 PM Eastern

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Immunome NASDAQ:IMNM

$9.20 -0.59 (-6.03%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$9.38 +0.18 (+1.90%)

As of 06/13/2025 06:24 PM Eastern

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Pharming Group NASDAQ:PHAR

$10.87 -0.69 (-5.97%)

As of 06/13/2025 04:00 PM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time